β-galactoside α2,6 sialyltransferase in human colon cancer: contribution of multiple transcripts to regulation of enzyme activity and reactivity withsambucus nigra agglutinin
Open Access
- 23 August 2000
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 88 (1) , 58-65
- https://doi.org/10.1002/1097-0215(20001001)88:1<58::aid-ijc9>3.0.co;2-q
Abstract
Colon cancer tissues display an increased activity of β-galactoside α2,6 sialyltransferase (ST6Gal.I) and an increased reactivity with the lectin from Sambucus nigra (SNA), specific for α2,6-sialyl-linkages. Experimental and clinical studies indicate a contribution of these alterations to tumor progression, but their molecular bases are largely unknown. In many tissues, ST6Gal.I is transcriptionally regulated through the usage of different promoters that originate mRNAs diverging in the 5`-untranslated regions. RT-PCR analysis of 14 carcinoma samples, all expressing an increased ST6Gal.I enzyme activity, and of the corresponding normal mucosa revealed the presence of at least 2 transcripts. One, containing the 5`-untranslated exons, Y+Z, is thought to represent the “housekeeping” expression, and another previously described in hepatic tissues. Both the Y+Z and the hepatic transcripts were detectable in normal and cancer tissues but that latter form had a marked tendency to accumulate in cancer. The extent of α2,6-sialylation of glycoconjugates, as determined by SNA-dot blot analysis, was markedly enhanced in all cancer specimens, but the level of reactivity only partially correlated with the level of enzyme expression. Western blot analysis revealed a strikingly heterogeneous pattern of SNA reactivity among cancer tissues. These data indicate that: i) during neoplastic transformation of colonic cells, ST6Gal.I expression may be modulated through a differential promoter usage; ii) the extent of α2,6-sialylation of cancer cell membranes is not a direct function of the ST6Gal.I activity, strongly suggesting the existence of other, more complex mechanisms of regulation. Int. J. Cancer 88:58–65, 2000.Keywords
This publication has 35 references indexed in Scilit:
- Differential Expression of α2,6-Sialyltransferase in Colon Tumors Recognized by a Monoclonal AntibodyHybridoma, 1998
- Transcription of the β-galactoside α2,6-sialyltransferase gene in B lymphocytes is directed by a separate and distinct promoter†Glycobiology, 1996
- Differentiation-dependent expression of human?-galactoside?2,6-sialyltransferase mRNA in colon carcinoma CaCo-2 cellsGlycoconjugate Journal, 1996
- Quantitative lectinhistochemical and immunohistochemical studies on the occurrence of alpha(2,3)- and alpha(2,6)-linked sialic acid residues in colorectal carcinomas. Relation to clinicopathologic featuresCancer, 1995
- Monoclonal antibody TKH2 to the cancer-associated epitope sialosyl Tn shows cross-reactivity with variants of normal colorectal goblet cell mucinPathology, 1994
- Clinical Aspects of Glycoprotein BiosynthesisCritical Reviews in Clinical Laboratory Sciences, 1993
- The expression of soluble and cell-bound α2,6 sialyltransferase in human colonic carcinoma CaCo-2 cells correlates with the degree of enterocytic differentiationBiochemical and Biophysical Research Communications, 1992
- Rat β-galactoside α2,6-sialyltransferase genomic organization: alternate promoters direct the synthesis of liver and kidney transcriptsGlycobiology, 1990
- The B cell antigen CD75 is a cell surface sialytransferase.The Journal of Experimental Medicine, 1990
- Comparative Study of the Levels of Sialyltransferases Responsible for the Formation of Sugar Chains in Glycoproteins and Gangliosides in Rat Liver and HepatomasJapanese Journal of Cancer Research, 1988